This week in TB R&D, we are highlighting a symposium hosted by The New York Academy of Sciences entitled “New Frontiers in Marine Drug Discovery” on May 20, 2011. This 1-day symposium will overview the current state of the art in Marine Biomedicine and its role in the context of the drug discovery process. Additional TB R&D news links are included.
Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.
In this week’s TB R&D update, we look at whether researchers should change their view and definitions of immunopathology in tuberculosis. The authors suggest that the term “caseous necrosis” should actually be split into three processes. The article is published in the February issue of Science Translational Medicine and is entitled “Tuberculosis immunopathology: the neglected role of extracellular matrix destruction.” Also, links to additional news in TB R&D are included.
In this week”s TB R&D update, The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational Biology in November 2010. Dr. Philip Bourne is a professor at University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology. In the interview, Dr. Bourne discusses his present research, use of structural bioinformatics to inform drug discovery, and the need for open access in research. Also, links to additional news in TB R&D are included.
In this week’s TB R&D update, we look at a novel vaccine that shows protection against TB before and after exposure. The research is published in the January issue of Nature Medicine and is entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure”. Also, links to additional news in TB R&D are included.